Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada
Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation for AVT04, a biosimilar to Alvotech’s Stelara (ustekinumab). The biosimilar will be marketed under the brand name Jamteki.
Jamteki is currently approved in a 45mg/0.5mL pre-filled syringe with a passive safety device for subcutaneous injection (PFS-SD) and a 90mg/mL PFS-SD.
This is the second biosimilar to receive marketing authorisation under an exclusive commercialisation partnership between the two companies.
Louis Pilon, president and CEO of JAMP Pharma, commented: “The introduction of Jamteki is in line with our current biosimilar product offering and showcases JAMP Pharma’s commitment to evolve in this market. Alvotech is an innovative and strategic partner, enabling Canadian patients to benefit from ustekinumab at a lower cost. Patients will also benefit from the expertise of our Patient Support Program – JAMP Care – for an optimal and seamless transition.”
Robert Wessman, chairman and CEO of Alvotech, added: “We are very pleased to receive marketing authorisation for our second biosimilar in Canada with JAMP Pharma. Strong demand for biosimilars in Canada indicates that there is a need for affordable quality biologics in the Canadian market. This is an important step for us and for our joint objective to offer broader access to more affordable healthcare.”
Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the …
Canada has become the first country in the world to grant full approval to the …